SYMBIOTEC PHARMALAB LIMITED

As of March 31, 2026, SYMBIOTEC PHARMALAB LIMITED has 64.26M shares outstanding.

As of March 31, 2026, SYMBIOTEC PHARMALAB LIMITED maintains a current ratio of 0.92, meaning it holds 0.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 34.01, indicating elevated leverage, while an interest coverage ratio of 9.04 demonstrates adequate ability to service its debt obligations.

Over the twelve months ended March 31, 2026, SYMBIOTEC PHARMALAB LIMITED posted a return on equity (ROE) of 11.19, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 8.62 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 6.54, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 8.83, useful for judging operating efficiency across full business cycles. The company generates approximately 5.24M in revenue per employee across its workforce of 1,659.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.27 indicates how many times SYMBIOTEC PHARMALAB LIMITED sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended March 31, 2026, SYMBIOTEC PHARMALAB LIMITED recorded 434.60M in income tax expense. That works out to an effective tax rate of 28.34, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 1.53B, leaving 1.10B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

Over the twelve months ended March 31, 2026, SYMBIOTEC PHARMALAB LIMITED generated 8.69B in revenue and converted that into 1.10B in net income, yielding earnings per share of 17.10. EBITDA reached 2.29B, while operating income came in at 1.85B.

As of March 31, 2026, SYMBIOTEC PHARMALAB LIMITED holds 373.59M in cash and equivalents against 3.91B in total debt, resulting in a net debt position of 3.78B. Total book value stands at 11.50B, with working capital of -420.21M providing operational flexibility.

SYMBIOTEC PHARMALAB LIMITED produced 1.75B in operating cash flow over the twelve months ended March 31, 2026. After subtracting -2.26B in capital expenditures, free cash flow totaled -511.26M - equivalent to -7.96 per share.

Over the twelve months ended March 31, 2026, SYMBIOTEC PHARMALAB LIMITED posted a gross margin of 63.70, reflecting its pricing power and cost economics. The operating margin of 21.24 and net profit margin of 12.64 provide insight into operational efficiency.